The current presentation covered the risk situation of healthcare workers during the pandemic concerning infection prevalence and risks according to specific occupations [1]. “New Jersey ranked second of the 50 US states with regard to infection,” Prof. Reynold A. Panettieri Jr (Rutgers Institute for Translational Medicine and Science, NJ, USA) described the setting of the research. A screening of nearly 4,000 employees of the Robert Wood Johnson teaching hospital (RWJ) included 74% women, 68.8% had direct patient contact, 44.1% were 20–39 years old, and 12.2% ≥60 years of age [2]. Markers of ongoing or previous SARS-CoV-2 infection were detected in about 10%. However, when looking further at the different occupations within the hospital, the rate varied. Being a phlebotomist carried the highest risk of a positive COVID-19 test with a proportion of 23.9%. Corresponding percentages in other occupations included maintenance/housekeeping 17.3% and food services 16.9%. Interestingly, rates of positive testing were 9.1% in nurses and 7.2% in doctors.
The Rutgers Corona Cohort consists of 548 healthcare workers (HCW) and 283 non-HCW. HCW from this cohort had regular patient exposure and worked at least 20 hours per week in the hospital [3]. Non-HCW included faculty, staff, and students. All participants had no prior history of a COVID-19 diagnosis. The proportion of positive tests for COVID-19 showed differences between hospital sites but, overall, HCW had higher rates of infection (7.3%) than non-HCW (0.4%). “So, the takeaway is, if you work in a hospital, you are more likely to get infected,” commented Prof. Panettieri.
When evaluating factors that might be associated with SARS-CoV-2 infection in HCW, working in an intensive care unit appeared protective, as was having diabetes, whereas working as a nurse, being obese, or being Hispanic increased the likelihood of infection [1]. “For nurses, working in an emergency room or on a medical floor rendered greater susceptibility to SARS-CoV-2 infection,” Prof Panettieri specified. Also, being staff of an operating room was a significant factor. Another interesting result was that among the HCW who were infected, those with the most severe disease had the highest IgG antibody titres.
Duration of symptom prevalence was additionally followed, and it was observed that even though most patients were not hospitalised, some of their symptoms were longer lasting. “Fatigue and body aches were symptoms that persisted in almost 20% of positive cases of HCW,” Prof Panettieri said, “fatigue lasted for 30 days in the 75-percentile, chest tightness nearly 30 days for the 75-percentile, and cognitive changes almost half a year. Hence, long haulers or long-haul symptoms persisted in HCW in those individuals who had mild disease without hospitalisation or ER visits” (see Figure).
Figure: Duration of symptoms in infected participants of the Rutgers Corona Cohort [1]
- Panettieri RA. Lessons Learned from a Large, Prospective COVID-19 Occupational Exposure Cohort. Session C026: Occupational COVID-19 exposure: risks and mitigation. ATS 2021 International conference, 14-19 May 2021.
- Barrett ES, et al. Open Forum Infect Dis. 2020;7(12):ofaa534.
- Barrett ES, et al. BMC Infect Dis. 2020;20(1):853.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Genetic risk variants responsible for COVID-19 predisposition Next Article
Air pollution: an underestimated negative prognostic factor for COVID-19 »
« Genetic risk variants responsible for COVID-19 predisposition Next Article
Air pollution: an underestimated negative prognostic factor for COVID-19 »
Table of Contents: ATS 2021
Featured articles
Letter from the Editor
COVID-19: What Pulmonologists Need to Know
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
Asthma – An Update
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Sleep Disorders – An Underestimated Problem
OSA: A risk factor for earlier cognitive decline
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Association between positive airway pressure treatment adherence and COVID-19 infection rates
COPD – What Is New
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
Metabolic Dysregulation and Lung Disease
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Best of the Posters
Air pollution in winter linked to more hospital admissions in ILD patients
Tobacco biomarkers do not improve prediction of lung cancer risk
Vaping identified as risk factor for asthma
Related Articles
November 28, 2019
Registry confirms nintedanib efficacy under real-life conditions
July 18, 2022
Novel PDE4B inhibitor offers breakthrough for IPF
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com